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Nonspanning Bivalent Ligands as Improved
Surface Receptor Binding Inhibitors
of the Cholera Toxin B Pentamer
ples of bivalent ligands targeting multimeric proteins are
more rare and include a study by Glick et al. [14] focusing
on the inhibition of influenza virus binding to immobilized
sialic acid residues by bivalent sialic acid derivatives,
as well as more recent studies by both Kitov et al. [15]
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Shiga-like toxin (SLT) pentamers were characterized. In3 Howard Hughes Medical Institute
4 Biomolecular Structure Center the latter two cases, bivalent ligands were characterized
that were able to span the distance between two closelyUniversity of Washington
Seattle, Washington 98195 spaced binding sites within a single subunit of the SLT
pentamer.
The rationale behind the design of the bivalent ligands
described in this report was influenced by results fromSummary
our previous line of investigation. Specifically, we have
been engaged in an overall effort to create high-affinityA series of bivalent ligands of varying length were
synthesized to inhibit the receptor-binding process of multivalent ligands targeting cholera toxin and heat-
labile enterotoxin. Cholera toxin (CT) and heat-labile en-cholera toxin. Competitive surface receptor binding
assays showed that significant potency gains relative terotoxin (LT) are two closely related AB5 bacterial toxins
that negatively affect the health of humans [17, 18]. CTto the constituent monovalent ligands were achieved
independently from the ability of the extended bivalent is produced by Vibrio cholerae, the causative agent of
the disease cholera. LT is produced by certain strainsligands to span binding sites within the toxin pentamer.
Several models that could account for the unexpected of pathogenic Escherichia coli and is known to cause
traveler’s diarrhea and children’s diarrhea. Binding toimprovement in IC50 values are examined, taking into
account crystallographic analysis of each ligand in the ganglioside GM1 receptor in the small intestine is a
critical first step in the pathway leading to the toxiccomplex with the toxin pentamer. Evidence is pre-
sented that steric blocking at the receptor binding effects of these proteins [19]. As such, developing high
affinity ligands that block the interaction between GM1surface may play a role. The results of our study sug-
gest that the use of relatively short, “nonspanning” and these protein toxins is an attractive route to pre-
venting the severe diarrhea stemming from infectionbivalent ligands, or monovalent ligands of similar to-
pology and bulk may be an effective way of blocking with V. cholerae or enterotoxigenic E. coli. Moreover,
such surface receptor binding inhibitors do not have tothe interaction of multimeric proteins with their cell
surface receptors. pass any membranes to exert their effect. Hence, they
can be virtually any size and carry substantial charge.
Previous multivalent constructs studied by us includeIntroduction
both pentavalent and branched pentavalent (or decava-
lent) ligands [20–22]. The most potent of these com-Multivalent ligands are an emerging theme in drug de-
sign [1, 2]. One of the hallmarks of multivalent binding pounds has an IC50 around 40 nM in an in vitro competi-
tive binding assay. Furthermore, the decavalent ligandsis enhanced binding affinity relative to corresponding
monovalent interactions. This is generally considered to were found to be substantially better at inhibiting recep-
tor binding (10-fold) than the corresponding pentava-be a result of the free energy savings associated with
paying the penalty for the loss of overall rotational and lent ligands. Thus, one conclusion that can be drawn
from these studies is that the improvement in IC50 dis-translational entropy only once for a multivalent com-
pound, rather than paying this penalty for each of the played by the decavalent ligands must be due to a sub-
stantial difference in affinity between the galactose frag-corresponding number of monovalent binding events.
ment within the pentavalent ligand and the rather short,Several models for the analysis of the thermodynamic
nonspanning bivalent galactose moiety within the deca-parameters associated with multivalent ligand binding
valent ligand. This prompted us to further investigatehave been proposed recently [3–5]. In addition, some
the properties of short, nonspanning bivalent ligands asmultivalent ligands, such as those targeting lectins like
surface receptor binding inhibitors of CT and LT.concanavalin A, have been shown to act primarily
This report describes a set of novel bivalent ligandsthrough a ligand-induced clustering or aggregation ef-
targeting the B pentamer of cholera toxin and heat-fect [6, 7].
labile enterotoxin. All of the compounds are too shortBivalent ligands represent the simplest class of
to effectively span the distance between any two bindingmultivalent ligand. Additionally, their smaller size and
sites within the toxin’s B pentamer. Hence, we refer toincreased synthetic accessibility have made them more
such compounds as “nonspanning” bivalent ligands. Wecommon in drug development programs [8–13]. Exam-
found, somewhat unexpectedly, that substantial gains in
surface receptor binding inhibition relative to the con-*Correspondence: erkang@u.washington.edu; wghol@u.washington.
stituent monovalent ligands was achieved indepen-edu
5 These authors contributed equally to this work. dently from the ability of the bivalent ligand to span
Chemistry & Biology
1206
Figure 1. Previously Studied Monovalent Ligands to CT and LT and Chemical Structure of Newly Synthesized Bivalent Ligands BV1–BV4
binding sites within the toxin pentamer, a system dis- a 100-fold increase in affinity relative to D-galactose.
Aided by the crystal structure of this compound boundtinctly different from those for which models were devel-
oped [3–7]. Consequently, the results presented here to CTB5 and LTB5, MNPG was used as a scaffold in the
may have substantial implications for the design of bio- design of subsequent series of monovalent antagonists.
active compounds that target cell surface receptor bind- The first was a collection of 15 compounds incorporating
ing processes. a small diverse set of ring systems through an alkyl
benzamide linkage meta to the nitro group of MNPG.
Results The morpholine-ring-containing compound (3-nitro-5-
(3-morpholin-4-yl-propylaminocarbonyl)phenyl)--D-
galactopyranoside (MP-MNPG, Figure 1), having goodLigand Design
The set of bivalent ligands presented here was based aqueous solubility and an additional 14-fold affinity gain
over MNPG, was then used in the design and synthesison monovalent compounds with much higher affinity for
the toxin pentamer than a simple D-galactose moiety. of the second series of compounds culminating in the
synthesis of N-{3-[4-(3-amino-propyl)-piperazin-1-yl]-We recently described the synthesis and character-
ization of a number of improved monovalent ligands propyl}-3-nitro-5-(3,4,5-trihydroxy-6-hydroxymethyl-
tetrahydro-pyran-2-yloxy)-benzamide (APP-MNPG) ofderived from the commercially available compound
m-nitrophenyl--D-galactopyranoside (MNPG, Figure 1) Figure 1 [25]. This compound features a propylpipera-
zine group that serves as an isosteric replacement of[23, 24]. In an early study, MNPG was found to display
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Figure 2. Synthesis of BV1–BV3
Conditions: (a) MeOH/H2O (pH 9.0); (b) di-t-butyl-dicarbonate, EtOH, 4C; (c) p-nitrophenylchloroformate, CH2Cl2; (d) DIEA/DMF; (e) 1:1 TFA/
CH2Cl2, 30 min; (f) dilute 3 in CH2Cl2 added dropwise to N-(2-aminoethyl)-carbamate hydrochloride in DMF, 22C; (g) H2 (1 atm) Pd/C (10%) in
EtOH; (h) excess dimethyl squarate, MeOH/H2O (pH 7.0); (i) MeOH/H2O (pH 9.0); (j) 1:1 TFA/CH2Cl2, 30 min.
the propylmorpholine moiety of MP-MNPG, and at the equivalents of dimethyl squarate under basic conditions
using previously reported conditions [20]. In our hands,same time provided an additional short linker terminat-
ing in a primary amine through which the compound the formation of the squaryl diamide proceeds efficiently
under the conditions employed without the need forcan be further modified. The IC50 of APP-MNPG alone
is around 350 M making it our most potent monovalent sugar protecting groups. The synthesis of BV2 and BV3
was slightly more involved (Figure 2). Starting fromcompound with good aqueous solubility so far. Thus,
we chose to incorporate APP-MNPG into the current 2-amino-1,3-propanediol (1) the amino group was pro-
tected with Boc using di-t-butyl-dicarbonate in dioxaneseries of bivalent ligands.
The structures of the newly synthesized compounds to give 2. Subsequent reaction with an excess of p-nitro-
phenyl chloroformate in dichloromethane gave the pre-are shown in Figure 1. BV1 is the shortest of the series
and contains a central squarate ring. BV2, BV3, and BV4 viously reported bis-nitrophenylcarbonate 3 [22]. This
compound was then reacted with an excess of APP-have longer, flexible linkers emanating from both ends
of 2-amino-1,3-propanediol via carbamate linkages. We MNPG in DMF in the presence of N,N-diisopropylethyl
amine (DIEA) to give Boc-protected BV2 which was thenchose the 2-amino-1,3-propanediol as the central ele-
ment of the bivalent ligand because it provides a primary treated with 1:1 TFA/CH2Cl2 yielding the free amine.
HPLC purification followed.amine that can be used in later conjugation to multiva-
lent scaffolds if desired. Both BV3 and BV4 contain the The synthesis of BV3 was the same as for BV2 through
intermediate 3 which was then treated with the commer-squarate linkage between the propylpiperazine of APP-
MNPG and the internal variable-length linker. In the case cially available benzyl N-(2-aminoethyl)-carbamate hy-
drochloride to give the orthogonally protected interme-of BV2, the propylpiperazine is coupled directly into
the carbamate linkage. Using an empirical formula for diate 4. The Cbz protecting groups of 4 were removed by
hydrogenolysis quantitatively over 10 percent palladiumestimating the effective end-to-end length of a linear
poly(ethylene glycol) chain in solution [26], we estimated on activated charcoal. The resulting diamine intermedi-
ate was then immediately brought up in methanol con-the effective length between the two MNPG moieties of
BV1–BV4 to be 17 A˚, 19 A˚, 22 A˚, and 27 A˚, respectively. taining an excess of dimethyl squarate under neutral
conditions to give 5 after HPLC. Treatment of 5 with anExtended lengths were determined to be 29 A˚, 35 A˚,
48 A˚ and 73 A˚, respectively for BV1–BV4. The calculation excess of APP-MNPG under basic aqueous conditions
gave Boc-protected BV3, which was deprotected andof effective and extended lengths was carried out for
comparison to the 35 A˚ distance between adjacent bind- purified in a manner analogous to BV2.
ing sites within the toxin B pentamer. For the synthesis of BV4 (Figure 3), compound 3 was
treated with a large excess of the diamine 4,7,10-trioxa-
1,13-tridecanediamine to give the crude diamine inter-Synthesis of Bivalent Ligands
The synthesis of BV1–BV4 is depicted in Figures 2 and mediate 6 after extractive work-up. The rest of the syn-
thesis was performed in a manner analogous to that of3. BV1 was obtained by treating APP-MNPG with 0.5
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Figure 3. Synthesis of BV4
Conditions: (a) Dropwise addition of 3 to neat 4,7,10-trioxa-1,13-tridecanediamine; (b) excess dimethyl squarate, MeOH/H2O (pH 7.0); (c) (i)
MeOH/H2O (pH 9.0) (ii) 1:1 TFA/CH2Cl2, 30 min.
BV3 after the removal of Cbz groups. In both cases, to 30 M compared to 338 M for APP-MNPG and
1700 M for MNPG, our previous benchmark lead. WithHPLC purification of intermediates 5 and 7 was neces-
sary to remove excess dimethyl squarate and other ac- respect to the most potent compound BV3, having an
IC50 of 9 M, this corresponds to an improvement overcumulated impurities.
APP-MNPG and MNPG of around 35- and 200-fold, re-
spectively.IC50 Values
The four compounds BV1–BV4 were tested using a com-
petitive GD1b surface receptor binding assay, a CT-HRP Crystallographic Analysis
As a first step toward better understanding of the lackdirect enzyme-linked assay (CT-DELA) [23]. Binding
curves for the bivalent compounds are shown in Figure of dependence on the linker length evident in the IC50
values, X-ray crystal structures of all four bivalent com-4 along with those previously obtained for MNPG and
APP-MNPG for comparison. From these curves, it is pounds bound to CTB5 were determined at high resolu-
tion. Crystals of space group C2 were obtained fromclear that all of the bivalent ligands are much better
at blocking CT conjugate binding to the GD1b-coated sitting drop experiments under conditions similar to
those previously reported for the crystallization of APP-microtitre plate surface compared to MNPG or APP-
MNPG. IC50 values for the series range from roughly 10 MNPG and related compounds [25]. Data collected at
Figure 4. Binding Curves and IC50 Values
Error bars represent the standard error of the
mean for at least two independent determina-
tions.
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Table 1. Crystallographic Data Collection and Refinement Statistics
Data Collection Statistics CTB5 BV1 CTB5  BV2 CTB5  BV3 CTB5  BV4
Source ALS 8.2.2 ALS 8.2.2 ALS 8.2.2 ALS 8.2.2
Wavelength (A˚) 1.0000 1.0000 0.9791 0.9626
Resolution (A˚) 1.60 1.44 1.35 1.35
Space group C2 C2 C2 C2
Number of observations 227,195 297,752 368,119 365,261
Unique reflections 63,041 81,971 100,384 104,314
Completeness (%) 96.0 (76.3) 92.4 (73.3) 91.3 (63.8) 94.2 (69.3)
I/(I) 18.3 (3.0) 14.4 (1.9) 19.5 (2.4) 13.5 (1.8)
Rmerge 6.4 (37.1) 8.3 (56.7) 5.9 (45.1) 8.1 (59.1)
Refinement Statistics
Number of residues 515 515 515 515
Water molecules 466 491 494 498
Bivalent ligand molecules 5 5 5 5
Other molecules None 1 TRIS, PEG 1 TRIS, PEG 1 TRIS, PEG
Ligand atoms - Site D 24 24 24 24
Ligand atoms - Site E 36 37 24 24
Ligand atoms - Site F 24 24 24 24
Ligand atoms - Site G 24 24 24 24
Ligand atoms - Site H 24 37 24 24
Rcryst (outer) 0.164 (0.217) 0.131 (0.192) 0.130 (0.208) 0.132 (0.236)
Rfree (outer) 0.193 (0.270) 0.184 (0.293) 0.171 (0.281) 0.174 (0.304)
Figure of merit 0.879 0.888 0.893 0.892
RMSD from ideal
Bond lengths (A˚) 0.013 0.013 0.013 0.012
Angles () 1.5 1.4 1.5 1.4
Chirality 0.097 0.092 0.088 0.086
the Advanced Light Source (ALS) provided data sets for ers (Figure 5A). The piperazine ring itself rests in a small,
shallow pocket formed between Glu11 and the face ofall four complexes at resolution ranging from 1.35 A˚
to 1.60 A˚. Data collection and refinement statistics are Tyr12. Interactions between the protein and the pipera-
zine ring in this region appear to be nonspecific, allowingshown in Table 1.
All of the crystals were in space group C2 yielding for multiple binding modes.
The cocrystal structure of CTB5 with BV2 was solvedstructures that contained one B pentamer in the asym-
metric unit and thus five unique views of the binding at a resolution of 1.44 A˚. In all five binding sites, strong
density corresponding to the nitrophenyl galactoside issite. In all of the binding sites of all of the structures,
very clear electron density is seen corresponding to the clearly visible. As before, there is additional density to
varying degrees in each of the binding sites at the piper-galactose ring and nitrobenzamide moiety. Furthermore,
in all the binding sites, the binding mode of the nitro- azine binding pocket (not shown). In two of the binding
sites, the density is strong enough to support a modelphenyl galactoside is identical to that seen for MNPG
[27] and APP-MNPG [25], where canonical water #2 is that includes the aminopropyl piperazine as before. In
this structure, extra density is seen in two places at thedisplaced from the binding site. To varying degrees,
additional density is seen that corresponds to the piper- crystal-packing interface along one edge of the pen-
tamer. One of these extra regions of density was a mole-azine ring and its aminopropyl extension. More impor-
tantly, no discernable electron density is visible in any cule of tris(hydroxymethyl)aminoethane (TRIS buffer)
and the other a segment of poly(ethylene glycol) (PEG)of the structures corresponding to the linker, or to a
second copy of the nitrophenyl galactose bound at a which was also present in the crystallization drop. The
TRIS model fits the electron density very well with itssubsite on the protein. In a few cases, extra density
is visible corresponding to other components of the primary amine nitrogen forming a hydrogen bond with
Glu11 2.72 A˚ away, and a water molecule 3.14 A˚ away.crystallization solution. A more detailed description of
the electron density seen in each cocrystal structure The other piece of extra density modeled as a segment
of PEG extends 5–9 A˚ between two symmetry-relatedfollows.
The cocrystal structure of CTB5 and BV1 was deter- pentamers.
The two cocrystal structures of CTB5 with BV3 andmined at a resolution of 1.60 A˚. In addition to the very
clear density corresponding to the galactoside portion with BV4 were both determined at a resolution of 1.35 A˚.
Electron density corresponding to the nitrophenylgalac-of the ligand, all five binding sites show additional den-
sity above Tyr12 corresponding to the aminopropyl pi- toside portion of the ligand was seen and modeled into
all five binding sites in both cases. Very little additionalperizine moiety. In four out of the five binding sites, the
electron density is not strong enough to construct a density was seen corresponding to the piperazine ring
in any of the five sites of the BV4 structure (Figure 5B).precise model. In the remaining site, enough electron
density is available to warrant building a more complete Some additional density was seen in the piperazine
pocket in the BV3 structure, but not enough to justifymodel including the piperazine ring and the propyl link-
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Figure 5. Electron Density and Fitted Model
(A) Electron density and model for BV1 in complex with CTB5. Electron density is contoured at 2 in a A-weighted (mFo–DFc) difference map.
(B) Electron density and model for BV4 in complex with CTB5. Electron density is contoured at 3 in a A-weighted (mFo-DFc) difference map.
modeling beyond the nitrobenzamide ring. Both struc- for the improvement in IC50 values for the bivalent series.
This is not meant to imply that transient, nonspecifictures had similar extra density to that seen in the BV2
structure that was again modeled as a molecule of TRIS interactions between the linker and the protein in solu-
tion are impossible. However, this would be very difficultfrom the buffer and a fragment of PEG. Hence, the crys-
tal structures containing BV3 and BV4, compounds that to test experimentally and would still fail to account for
the collective improvement in IC50 of all the compoundscould potentially span two binding sites if their linkers
were substantially stretched out, do not provide any tested because the structure and length of the linkers
vary substantially. Also, a subsite for the pendant sugarevidence for such behavior.
seems an unlikely explanation as well because the exis-
tence of a such a subsite for the galactose moiety hasDiscussion
not yet been seen in any previous crystal structures
of the toxin B pentamer in complex with a variety ofGiven the fact that the effective linker lengths for the
monovalent or multivalent ligands, including those con-series range from 17 A˚, in the case of BV1, to roughly
taining D-galactose alone at high concentration [17, 28].27 A˚ in the case of BV4, the substantial improvement
Intermolecular cross-linking and subsequent forma-in IC50 displayed by the bivalent compounds indepen-
tion of aggregates and/or clusters is another possibilitydent of their respective linker lengths (Figure 4) is quite
that has been shown to play a significant role in otherunexpected and intriguing since the distance between
systems, such as the binding of concanavalin A toadjacent binding sites is 35 A˚ (Figure 6). Several scenar-
multivalent displays of mannose [6, 7]. In our currentios exist that might account for this increased potency
assay system, the total concentration of ligand at theincluding the following: (1) favorable interactions be-
IC50 is present at a 105 molar excess over the CT-HRPtween the linker and/or pendant sugar portion of the
conjugate, which is held at a constant concentration ofligands with the protein surface, (2) intermolecular cross-
around 100 pM. Hence, intermolecular cross-linking oflinking of toxin pentamers during the incubation step of
toxin pentamers under these conditions is very unlikely.the competitive binding assay, (3) avidity-based enhance-
Unfortunately, these very dilute conditions can’t be em-ments due to bivalent binding of the ligand within a
ployed within the detection limits of dynamic light scat-single pentamer, (4) electrostatic effects and, (5) steric
tering (DLS) experiments, which would allow one to rig-blocking effects in the competitive surface binding
orously test this assumption. However, preliminary DLSassay. Each of these possibilities is examined in the
studies of the best bivalent compound, BV3, togetherfollowing discussion.
with the B pentamer both at much higher concentrationsBased on the fact that no electron density is seen in
(10–50 M) than employed in the assay indicated thatany of the crystal structures corresponding to the linker
very little of the bulk sample contained species largeror pendant sugar, one may conclude that additional
than the B pentamer alone. Additionally, we have pre-favorable interactions involving these portions of the
bivalent ligand with the protein are not a primary reason viously shown very clearly by DLS measurements that
Nonspanning Bivalent Ligands
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Figure 6. Relative Dimension of CTB5 and BV1–BV4
Effective linker lengths between MNPG amide group nitrogen atoms were determined in a manner described previously [26] and are listed
beside the compound labels. Values in parentheses indicate extended linker lengths from the same end point atoms. Nonenergy-minimized
models for each bivalent ligand were constructed starting from the structure of APP-MNPG (green) bound to CTB5 [25]. Figure made using
RASTER3D [40].
ligand-induced cross-linking is not a large component each of the five B monomers, the remaining 25 of the
35 charged residues on the bottom of the pentamer areof the binding between the toxin pentamers and any
of the much more potent pentavalent and decavalent positively charged lysines and arginines. This electro-
static anticomplementarity, along with expected attenu-ligands under conditions where the ligand is held in
great excess [20–22]. ating effects of the high ionic strength phosphate-buf-
fered saline solution used in the assay, render favorableEnhancements from intramolecular, bivalent binding
of the ligands are a third possibility (Figure 6). However, electrostatic effects unlikely to be the cause of the IC50
improvement of the bivalent compounds over theirdespite the fact that the shortest distance between two
adjacent binding sites is only 35 A˚, the radial symmetry monovalent counterparts.
A final intriguing possibility is that of steric blockingof the pentamer, combined with a convoluted protein
surface path, allows only the longest compound, BV4 at the toxin binding surface. One could argue that when
the toxin’s five binding sites are partially saturated, thein an extended form, to present a pendant copy of the
galactoside to an adjacent binding site without substan- steric bulk of the pendant portion of the nonspanning
bivalent ligands may be able to prevent close approachtial conformational restriction of the linker. It should be
noted, however, that the 27 A˚ effective linker length of of the pentamer to the microtitre plate surface bearing
the immobilized ganglioside, thus indirectly blocking ac-BV4 is still significantly shorter than the distance of 35 A˚
between adjacent binding sites within the B pentamer. cess of the surface receptors to the unoccupied sites.
Such a phenomenon would be similar to known “stericSince the IC50 of BV4 is not dramatically different from
the other bivalent ligands including even BV1, one may stabilization” effects reported for the large polyacryl-
amide-based polyvalent inhibitors of influenza virusconclude that the ability to span two binding sites alone
is not a major contributor to the IC50 improvement dis- agglutination [29–31]. Also, the pendant portion of the
longer bivalent ligands may be able to sterically occludeplayed by the series as a whole.
Electrostatic effects should be considered as well. access to unoccupied receptor binding sites. Conceiv-
ably, the combination of these two effects could driveEach of the bivalent ligands is expected to carry three
positive charges under the nearly neutral aqueous con- the equilibrium of conjugate binding toward the non-
plate-bound state during the incubation step of theditions employed in the assay. Therefore, if the “bottom”
surface of the toxin pentamer displayed many negatively assay, resulting in a roughly equal apparent decrease
in the IC50 for all of the bivalent ligands. Based on thischarged residues, one could invoke electrostatic com-
plementarity to explain the IC50 improvement. However, model, one would predict that very short bivalent ligands
would yield the smallest potency gains. Consistent withwith the exception of two glutamatic acid residues in
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spectra were recorded using a Bruker AC-300 operating at 300this prediction is the observation that the shortest biva-
MHz. Samples were dissolved in methanol-d4 and not subjected tolent ligand BV1 shows the least dramatic improvement,
spinning during spectra acquisition. LC-MS characterization wasonly 10-fold relative to compound APP-MNPG (Figure
performed using an Agilent 1100 series instrument equipped with
4). Additionally, the model implies that a monovalent a variable wavelength detector coupled to an Agilent 1100 MSD-
ligand with an analogous linker region, but missing the Trap SL electrospray ion trap mass spectrometer operating in posi-
pendant copy of the galactoside, might be nearly as tive ion mode. Reported values for the molecular ion [M H] of
target compounds refer to those obtained during LC-MS analysiseffective as the bivalent version. Experiments designed
either during or after purification. Columns used for both preparativeto thoroughly test this hypothesis are in progress.
C18 reverse-phase HPLC purification and LC-MS characterizationIn addition to examining the collective behavior of the
were purchased from Agilent Technologies (Zorbax SB-AQ, 5 m,bivalent compounds reported here, internal compari-
4.6 or 21.2 150 mm). Analytical and preparative HPLC purifications
sons are also worth noting. The IC50 for APP-MNPG is were performed using mixed solvent systems comprised of acetoni-
around 350M, between that of the bivalent compounds trile and 0.1% TFA in water at a flow rate of either 0.5 ml min	1
(10–30 M) and MNPG (1.7 mM). This indicates that (analytical) or 30 ml min	1 (preparative).
N-Boc-2-amino-1,3-propanediol (2). 2-amino-1,3-propanediolthe dipropylpiperazine moiety of APP-MNPG, and more
(2.0 g, 21.5 mmol) was dissolved in 20 ml of absolute ethanol. Di-than likely, of the bivalent ligands, is engaging in at least
tert-butyl-dicarbonate (5.6 g, 26 mmol) was dissolved in 20 ml ofsome favorable interactions within the GM1 binding site.
absolute ethanol in a 50 ml addition funnel and added dropwise toThis is consistent with the previous crystallographically
the solution of 2-amino-1,3-propanediol at 4C over a period of one
observed binding mode of APP-MNPG bound to CTB5, hour. The solution was then gently warmed to 37C and stirred
in which electron density is seen for the piperazine ring vigorously for another hour. The solvent was removed under vacuum
continuing through the terminal propylamine where these and the remaining clear oil was suspended in a 1:1 solution of EtOAc
and hexane. The mixture was heated until all solids were dissolved.segments of the ligand contact the protein surface [25].
Then, additional hexane was added until the solution becameAs a result, one can either describe BV1–BV4 as bivalent
slightly cloudy. The resulting suspension was then placed in a 4Cversions of APP-MNPG, where the dipropylpiperazine
freezer overnight to promote crystallization. Filtration gave largemoiety is considered part of the pharmacophore, or bi-
white flakes (3.99 g, 85% yield). 1H-NMR (CDCl3) 
 4.87 (br. m, 1H),valent versions of MNPG where the dipropylpiperazine 3.57 (s, CH2, 4H), 1.44 (s, Boc, 9H).
is considered to be part of the linker while incidentally N-Boc-2-amino-1,3-bis (4-nitrophenyloxy-carbonyloxy)propane (3).
providing additional favorable interactions with the pro- Compound 3 was prepared as previously described [22].
{2-[3-(2-Benzyloxycarbonylamino-ethylcarbamoyloxy)-2-tert-tein near to where the MNPG moiety is bound. Addition-
butoxycarbonylamino-propoxycarbonylamino]-ethyl}-carbamically, the IC50 values shown in Figure 4 for BV2, BV3, and
acid benzyl ester (4). A solution of the dicarbonate 3 (200 mg, 0.38BV4 differ from each other by less than a factor of two,
mmol) in 20 ml CH2Cl2 was added dropwise over a period of 3 hrmaking them essentially the same within the context of to a DMF solution containing benzyl-N-(2-aminoethyl)-carbamate
the assay format. hydrochloride (500 mg, 2.2 mmol) and 500 l of diisopropylethylam-
ine (DIEA). When the addition was complete, the solvent was re-
moved under vacuum and the remaining clear residue dissolved inSignificance
5 ml of MeOH and purified by preparative HPLC to give 196 mg of
4. Yield: 82%. ESI-MS m/z 632.1 [M H], 532.1 (-Boc). 1H-NMR: 
Diarrheal diseases such as those caused by the action
7.34-7.28 (m, aromatic H), 5.06 (s, 4H), 4.2-3.8 (br. m, 5H), 3.19 (s,of cholera toxin and the related heat-labile enterotoxin 8H), 1.41 (s, 9H).
from certain pathogenic strains of E. coli continue to {2-[2-(2-methoxy-3,4-dioxo-cyclobut-1-enylamino)-ethylcarba-
threaten the health of millions of people each year. As moyloxy]-1-[2-(2-methoxy-3,4-dioxo-cyclobut-1-enylamino)-ethyl-
carbamoyloxymethyl]-ethyl}-carbamic acid tert-butyl ester (5). Thepart of a continuing effort to create effective antago-
synthesis of 5 was performed in two steps. Hydrogenolysis of Cbznists of toxin receptor binding, the findings described
groups was accomplished by stirring a solution 4 (166 mg, 0.26in this report reveal that the use of nonspanning biva-
mmol) in 4 ml EtOH containing approximately 200 mg of (10%) Pd/Clent ligands can produce potency gains of 10- to 100-
under H2 (1 atm) for 4.5 hr. The reaction was then checked by LC-fold beyond what would be expected from the mere MS that indicated when the reaction was complete. After filtration to
presence of an additional copy of the monovalent bind- remove the catalyst and solvent removal, 88 mg of the deprotected
ing element. A combination of solution and crystallo- intermediate was obtained as clear oil. Yield: 92%. ESI-MS m/z
364.1 [M H]. This material was brought up in 3 ml of MeOHgraphic studies were used to test various hypotheses
along with dimethyl squarate (360 mg, 50-fold excess) and stirredthat would account for the increased potency of the
overnight. The reaction was checked by LC-MS to confirm comple-bivalent ligands. The results suggest that steric
tion and then purified by preparative HPLC under standard condi-
blocking may play a role in the competitive surface tions giving 76 mg of purifed 5 as colorless syrup. Yield: 66%. ESI-
receptor binding inhibition. Consequently, the use of MS m/z 584.0 [M H], 484.0 (–Boc).
bivalent or nonbivalent compounds with similar, or (3-{2-[2-(3-amino-propoxy)-ethoxy]-ethoxy}-propyl)-carbamic
acid 3-(3-{2-[2-(3-amino-propoxy)-ethoxy]-ethoxy}-propylcarba-even greater steric bulk than those reported here may
moyloxy)-2-tert-butoxycarbonylamino-propyl ester (6). Dicarbonaterepresent an attractive general design strategy for
3 (400 mg, 0.076 mmol) was added drop-wise over a period of 3 hrblocking the binding capability of a variety of multimeric
to 20 ml of the diamine 4,7,10-trioxa-1,13-tridecanediamine withproteins to their cell surface receptors. The present
rapid stirring. The sample was diluted with 50 ml of water and the
findings are also likely to provide motivation for future organic layer separated. Extraction of the aqueous layer with 2 
studies aimed at probing the feasibility of incorporat- 50 ml CH2Cl2 followed. The organic fractions were combined and
ing a steric blocking element into a variety of multiva- washed with water until colorless. The solvent was dried over
MgSO4, filtered, and removed under vacuum to give 280 mg of a palelent drug design strategies.
yellow syrup which was used directly without further purification or
characterization in the synthesis of 7. Yield: 53%.Experimental Procedures
[3-(2-{2-[3-(2-methoxy-3,4-dioxo-cyclobut-1-enylamino)-prop-
oxy]-ethoxy}-ethoxy)-propyl]-carbamic acid 2-tert-butoxycarbon-Synthetic Chemistry
ylamino-3-[3-(2-{2-[3-(2-methoxy-3,4-dioxo-cyclobut-1-enylamino)-Unless otherwise noted, commercially available reagents and sol-
vents were used as purchased without further purification. 1H-NMR propoxy]-ethoxy}-ethoxy)-propylcarbamoyloxy]-propyl ester (7).
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Compound 6 (280 mg, 0.31 mmol) was dissolved in 10 ml of MeOH. triplicate data sets of at least ten different concentrations for each
ligand by nonlinear regression using the Prism software packageDimethyl squarate (1.0 g, 50-fold excess) was then added while
stirring. The solution was stirred for an additional 24 hr at room (version 3.0, GraphPad Software, Inc.). Reported values are the aver-
age of at least two separate experiments.temperature and then purified directly by preparative HPLC. Prior to
solvent removal by rotary evaporator, the acidic aqueous fractions
obtained from purification were neutralized to pH 7.0 using concen- Protein Expression and Purification
trated ammonium hydroxide to prevent removal of the Boc group. Toxin B pentamers were obtained as described previously [23].
The sample was desalted using a Waters SepPak C18 cartridge. Briefly, wild-type cholera toxin B subunit was expressed by E. coli
Elution from the cartridge with pure MeOH followed by solvent re- strain Top10 containing a pBAD/CTB5 vector. The vector is con-
moval gave 167 mg of pale yellow oil (7). Yield: 45%. ESI-MS m/z trolled by a pBAD promoter and contains an ampicillin resistance
904.4 [M H], 804.4 (–Boc), 1H-NMR: 
 4.38, 4.35 (d, 4H), 4.03 (br. marker. Cells were grown at 30C in Luria-Bertani Broth (LB) to OD600
m, 5H), 3.70–3.49 (m, 30H), 3.18 (t, 4H), 1.85 (quintet, 4H), 1.74 around 0.4 before overnight induction, initiated by the addition of
(quintet, 4H), 1.43 (s, 9H). 0.2% arabinose. Whole-cell lysates were prepared by resuspending
Bivalent compound BV1. APP-MNPG (10 mg, 0.018 mmol) and the cell pellet in lysis buffer (20 mM Tris-HCl [pH 7.5], 0.1 mM DTT,
dimethyl squarate (1 mg, 0.007 mmol) were brought up in 2 ml of a 0.2 mM EDTA, and 200 mM NaCl) and lysing the cells by two rounds
solution of 1:1 aqueous NaHCO3 and MeOH (pH  9). The solution of French press. The supernatant from centrifuged lysate was col-
was stirred at room temperature overnight. After filtration to remove lected and batch bound to immobilized D-galactose resin (Pierce)
any precipitated NaHCO3, the solution was acidified with a drop of for 30 min to 16 hr at 4C, washed with Buffer G (50 mM Tris-HCl
glacial acetic acid and subjected to HPLC purification. After removal [pH 7.4], 200 mM NaCl, 1 mM EDTA, and 3 mM NaN3), and eluted
of the solvent, the clear residue was dissolved in 1 or 2 ml of water with Buffer G  300 mM D-galactose (Fluka). Residual galactose
and lyophilized to give 11 mg of BV1 as the TFA salt. Yield: 61%. was removed from purified CTB5 by dialysis against Buffer G.
ESI-MS m/z 1133.5 [M H] 567.5 [M2H]2. 1H-NMR: 
 8.35 (s,
2H), 8.17 (s, 2H), 8.00 (s, 2H), 5.70,5.69 (d, 2H anomeric), 4.0–3.53 Crystallization
(m, 14H, overlapping resonances from galactose rings), 3.51 (t, 4H), Crystals of CTB5 complexed with BV1 grew from sitting drops con-
3.05 (br. m, 8H), 2.86 (br. t, 4H), 2.01–1.91 (m, 8H). taining 1 l of 30% PEG 300, 50 mM NaCl, and 100 mM Tris-HCl
Bivalent compound BV2. Compound 3 (5 mg, 0.010 mmol) and (pH 7.5) mixed with 1 l of 2.30 mM BV1 mixed with CTB5 at 5 mg
APP-MNPG (20 mg, 0.036 mmol) were dissolved in 250 l of DMF mL	1. The final molar ratio of BV1 to B pentamer was 5:1.
in a small vial containing a micro stir bar. N,N-diisopropylethylamine Crystals of CTB5 complexed with BV2 grew from sitting drops
(30 L) was then added. The vial was sealed and transferred to a containing 1 l of 38% PEG 300, 50 mM NaCl, and 100 mM Tris-
37C oven and kept stirring overnight. The sample was diluted with HCl (pH 7.5) mixed with 1 l of 2.3 mM BV2 mixed with CTB5 at
MeOH and checked for completion by LC-MS. Upon completion the 5 mg mL	1. The final molar ratio of BV2 to B pentamer was 5:1.
sample was purified by preparative HPLC. After solvent removal, Crystals of CTB5 complexed with BV3 grew from sitting drops
the clear residue was dissolved in 1 or 2 ml of water and lyophilized containing 500 nL of 12% PEG 8000, 50 mM NaCl, 100 mM Tris-
to give 10 mg of the Boc-protected target compound; ESI-MS m/z HCl (pH 7.5), and 20 mM MgCl2 mixed with 500 nL of 2.3 mM BV3
1298.8 [M H], 650.1 [M2H]2. Deprotection using 2 ml of 1:1 mixed with CTB5 at 4.8 mg mL	1. The final molar ratio of BV3 to B
TFA/CH2Cl2, subsequent solvent removal and relyophilization gave pentamer was 5.2:1.
9 mg of the final compound. Yield: 79%. ESI-MS m/z 1198.6 [M Crystals of CTB5 complexed with BV4 grew from sitting drops
H], 600.0 [M2H]2. 1H-NMR: 
 8.34 (s, 2H), 8.16 (s, 2H), 7.98 (s, containing 1 l of 16% PEG 8000, 50 mM NaCl, 100 mM Tris-HCl
2H), 5.69 (s, 2H, anomeric), 4.3 (m, 4H), 4.2–3.8 (m, 6H), 3.7–3.69 (d, (pH 7.5), and 20 mM MgCl2 mixed with 1 l of 2.3 mM BV4 mixed
4H), 3.60–3.0 (m, 35H), 2.05 (m, 4H), 1.89 (m, 4H). with CTB5 at 5 mg mL	1. The final molar ratio of BV4 to B pentamer
Bivalent compound BV3. APP-MNPG (60 mg, 0.113 mmol) and was 5:1.
compound 5 (12 mg, 0.020 mmol) were brought up in 2 ml of a Mature, well-defined crystals formed within 48 hr of sitting drop
solution of 1:1 aqueous NaHCO3 and MeOH (pH  9). The solution preparation and were flash-frozen for collection at the synchrotron
was stirred at room temperature overnight. After filtration to remove light source. Glycerol (30%) in mother liquor was used as a cryopro-
any precipitated NaHCO3, the solution was acidified with a drop of tectant for the CTB5:BV3 complex and the CTB5:BV4 complex. No
glacial acetic acid and subjected to HPLC purification. After solvent cryoprotectant was added before flash-freezing the crystals con-
removal, the clear residue was dissolved in 1 or 2 ml of water and taining BV1 and BV2. All crystals were of space group C2, and had
lyophilized to give 18 mg of Boc-protected BV3; ESI-MS m/z 1574.5 a unit cell that was isomorphous to that of the previously determined
[MH], 788.0 [M2H]2. Deprotection using 2 ml of 1:1 TFA/CH2Cl2, structure of CTB5 complexed with GM1-OS (PDB Accession Number
subsequent solvent removal and relyophilization gave 17 mg of the 3chb) [32].
final compound. Yield: 56% from 5. ESI-MS m/z 1476.6 [M H],
738.0 [M2H]2. 1H-NMR: 
 8.33 (s, 2H), 8.15 (s, 2H), 7.98 (s, 2H),
Structure Determination and Refinement
5.69 (s, 2H), 4.5–3.0 (br. m, 53H), 2.05 (br. m, 12H).
Crystal diffraction data was collected at synchrotron radiation level
Bivalent compound BV4. APP-MNPG (70 mg, 0.132 mmol) and
beamline 8.2.2 at the Advanced Light Source (ALS) at Berkeley
compound 7 (10 mg, 0.011 mmol) were brought up in 2 ml of a
National Lab, Berkeley, CA. X-ray diffraction data for CTB5:BV1 andsolution of 1:1 aqueous NaHCO3 and MeOH (pH  9). The solution CTB5:BV2 were measured at a wavelength of 1.0000 A˚. X-ray diffrac-was stirred at room temperature overnight. After filtration to remove
tion data for CTB5-BV3 was measured at a wavelength of 0.9791 A˚.any precipitated NaHCO3, the solution was acidified with a drop of X-ray diffraction data for CTB5:BV4 was measured at a wavelengthglacial acetic acid and subjected to HPLC purification. After solvent
of 0.9626 A˚. Diffraction images were integrated and scaled with
removal, the clear residue was dissolved in 1 or 2 ml of water and
HKL2000 and TRUNCATE [33]. Phases were determined using the
lyophilized to give 12 mg of Boc-protected BV4; ESI-MS m/z 1894.8
molecular replacement program MOLREP [34]. CTB5 complexed[M H], 948.4 8 [M2H]2. Deprotection using 2 ml of 1:1 TFA/
with GM1-OS (PDB Accession Number 3chb) with ligand and waters
CH2Cl2, subsequent solvent removal and relyophilization gave 11 removed, was used as a search model for all data sets.
mg of the final compound. Yield: 56% from 7. ESI-MS m/z 1476.6
Rigid body, TLS, isotropic, and anisotropic model refinement were
[M H], 738.0 [M2H]2. 1H-NMR: 
 8.33 (s, 2H), 8.16 (s, 2H), 7.98
carried out in REFMAC5 [35] and ARP/WARP [36] within the CCP4
(s, 2H), 5.69 (s, 2H), 4.3 (br. m, 4H), 3.97, (m, 4H), 3.85 (m, 2H), 3.8–2.8
suite of programs. Individual anisotropic temperature factors were
(br. m, 77H), 2.05 (br. m, 12H), 2.8 (m, 4H), 1.74 (m, 4H).
applied for higher resolution structures BV2, BV3, and BV4 near the
end of refinement. Individual anisotropic values varied markedly
between subunits. Real-space manual modeling and automated wa-IC50 Determinations
The GD1b direct enzyme linked assay (DELA) was carried out in a ter picking was done with Xfit [37]. A general refinement scheme
began with a rigid body refinement, and subsequent restrained re-96-well format as previously reported [23]. Samples consisted of 6
ng mL	1 CTB5 pentamer conjugated to horseradish peroxidase finements while increasing the resolution. Iterative building of the
water shell involved automated and manual water placement with(CTB-HRP) incubated for 2 hr in the presence of ligand at different
concentrations. IC50 values were calculated from either duplicate or XFIT and ARP/WARP [36] using SFCHECK [38] and WHATCHECK
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[39] along with manual inspection to discern incorrectly modeled 13. Abadi, A.H., Lankow, S., Hoefgen, B., Decker, M., Kassack,
M.U., and Lehmann, J. (2002). Dopamine/serotonin receptorwaters. TLS parameters and anisotropic refinement parameters for
high-resolution structures were then employed during the final ligands, part III: synthesis and biological activities of 7,7-alky-
lene-bis-6,7,8,9,14,15-hexahydro-5h-benz D indolo 2,3-g aze-rounds of refinement. Partial ligand subtracted maps were used to
help refine more “flexible” regions of the ligands. “MNPG sub- cines-application of the bivalent ligand approach to a novel type
of dopamine receptor antagonist. Arch. Pharm. 335, 367–373.tracted” maps gave good indications of proper piperazine ring
placement when applicable. Rfree, established after scaling, was the 14. Glick, G.D., Toogood, P.L., Wiley, D.C., Skehel, J.J., and
Knowles, J.R. (1991). Ligand recognition by influenza virus: thequality determinant for all refinement steps. The geometric descrip-
tion of the ligands, TRIS molecule, and PEG fragment for refmac binding of bivalent sialosides. J. Biol. Chem. 266, 23660–23669.
15. Kitov, P.I., Shimizu, H., Homans, S.W., and Bundle, D.R. (2003).(“cif” file) were generated by feeding a ligand-coordinate file to the
website http://davapc1.bioch.dundee.ac.uk/prodrg. The output cif Optimization of tether length in nonglycosidically linked bivalent
ligands that target sites 2 and 1 of a shiga-like toxin. J. Am.file was then manually inspected with reference to the Cambridge
Structural Database before being used in REFMAC5. Chem. Soc. 125, 3284–3294.
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Accession Numbers
Crystal structure coordinates for BV1, BV2, BV3, and BV4 in complex
with the B pentamer of cholera toxin have been deposited in the
Protein Data Bank (PDB Accession Numbers 1rcv, 1rd9, 1rdp, and
1rf2, respectively).
